Search
SOLACI Congress
HomeFile

File

View Category
Coronary disease

¿What Should We Do About Significant Coronary Lesions in TAVR?

Aortic stenosis and coronary artery disease (CAD) share risk factors, which means significant lesions will coexist in...
Dr. Carlos Fava -
Learn More
Structural heart disease

ESC 2024 | RHEIA Trial: Transcatheter vs. Surgical Replacement in Women

The RHEIA trial is the first randomized, women-exclusive international study aimed to assess the safety and efficacy...
Dr. Omar Tupayachi -
Learn More
Antithrombotic Anticoagulants

ESC 2024 | POPular PAUSE TAVI: Continuation vs. Discontinuation of Oral Anticoagulant Therapy During TAVI

Due to their advanced age and comorbidities, many patients with severe aortic stenosis scheduled for transcatheter aortic...
Dr. Omar Tupayachi -
Learn More
Chronic Coronary Syndromes

ESC 2024 | NOTION 3 Trial: Percutaneous Coronary Intervention in Patients with a Planned Transcatheter Aortic Valve Implantation

The relationship between aortic stenosis and valve disease is well established, with revascularization rates in this population...
Dr. Omar Tupayachi -
Learn More
Other

ESC 2024 | TRI.Fr: Transcatheter Tricuspid Repair for the Treatment of Tricuspid Regurgitation

Right-sided heart failure and tricuspid regurgitation (TR) are associated with poor quality of life and an increased...
Dr. Omar Tupayachi -
Learn More
Mitral valve

ESC 2024 | MATERHORN Trial: Transcatheter vs. Surgical Mitral Repair in Patients with Heart Failure and Secondary Mitral Regurgitation

European guidelines consider transcatheter therapy as an alternative for patients with secondary mitral regurgitation who are not...
Dr. Omar Tupayachi -
Learn More
Mitral valve

ESC 2024 | RESHAPE-HF2: MitraClip in Heart Failure and Moderate to Severe Mitral Regurgitation

The aim of this study was to assess the effectiveness of MitraClip in patients with secondary mitral...
Dr. Omar Tupayachi -
Learn More
Antiplatelet

ESC 2024 | QUADRO Trial: Efficacy and Safety of the First Quadruple Therapy Single Pill in Resistant Hypertension Patients

Researchers conducted an international, randomized, parallel-group study with a superiority design over a 16-week period. The doses...
Dr. Omar Tupayachi -
Learn More

SOLACI is the reference organization for Latin American cardiovascular interventionism.

Last News

TRILUMINATE: Liver and Kidney Failure in Tricuspid Valve Edge-to-Edge Repair

Dr. Carlos Fava - 0
Severe tricuspid regurgitation (TR) will affect roughly 3% of the 65+ population and may lead to liver and kidney failure, which will cause ascites...

Secondary Access in TAVI: Is Transradial Approach our Best Bet?

Dr. Omar Tupayachi - 0
In some countries, transcatheter aortic valve implantation (TAVI) has become the treatment of choice for patients with severe symptomatic aortic stenosis. Primary transfemoral access...

FAVOR III Europa Sub-Analysis: Coronary Revascularization Deferral Based On QFR vs FFR

Dr. Andrés Rodríguez - 0
When it comes to intermediate coronary lesion revascularization decision making, functional assessment is the recommended. At present, several indices are used, such as fractional...

Institutional News

Cuba Sessions 2025 | Young Interventional Cardiologists Contest

solaci - 0
Call for Case Submission L SOLACI Regional Sessions - 18° Central America & The Caribbean Region - It is with great pleasure that we hereby...

Hemodynamics and Interventional Cardioangiology Hybrid Training Course SOLACI-CACI

solaci - 0
We are now open for registration to the hybrid training course on Hemodynamics and Interventional Cardioangiology for Technicians and Nurses SOLACI-CACI 2025 Find all course...

Check out the best images of the El Salvador 2024 Sessions

solaci - 0
Review the highlights of the XLIX SOLACI Regional Sessions held at the Intercontinental Hotel in San Salvador, El Salvador between November 7 and 8,...

Access

Adolfo Alsina 2653 · Piso 2H · CABA · Buenos Aires · Argentina · (5411) 4954 7173 · info@solaci.org · solaci.org · Terms of Use -Privacy Policy